The DOI matches its Crossref record; 157 of the 157 references it cites were found in a registry or an index.
Treatment resistant schizophrenia: Clinical, biological, and therapeutic perspectives
Open accessAbstract
Treatment resistant schizophrenia (TRS) refers to the significant proportion of schizophrenia patients who continue to have symptoms and poor outcomes despite treatment. While many definitions of TRS include failure of two different antipsychotics as a minimum criterion, the wide variability in inclusion criteria has challenged the consistency and reproducibility of results from studies of TRS. We begin by reviewing the clinical, neuroimaging, and neurobiological characteristics of TRS. We further review the current treatment strategies available, addressing clozapine, the first-line pharmacological agent for TRS, as well as pharmacological and nonpharmacological augmentation of clozapine including medication combinations, electroconvulsive therapy, repetitive transcranial magnetic stimulation, deep brain stimulation, and psychotherapies. We conclude by highlighting the most recent consensus for defining TRS proposed by the Treatment Response and Resistance in Psychosis (TRRIP) Working Group, and provide our overview of future perspectives and directions that could help advance the field of TRS research, including the concept of TRS as a potential subtype of schizophrenia.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Biological insights from 108 schizophrenia-associated genetic loci
Schizophrenia Working Group of the Psychiatric Genomics Consortium (2014) · Nature · doi:10.1038/nature13595 · Cited by 7,577
Common polygenic variation contributes to risk of schizophrenia and bipolar disorder
The International Schizophrenia Consortium (2009) · Nature · doi:10.1038/nature08185 · Cited by 4,821
Clozapine for the Treatment-Resistant Schizophrenic: A Double-blind Comparison With Chlorpromazine
Kane, J. (1988) · Archives of General Psychiatry · doi:10.1001/archpsyc.1988.01800330013001 · Cited by 4,156
A Randomized Trial of Deep-Brain Stimulation for Parkinson's Disease
Deuschl, G., Schade-Brittinger, C., Krack, P., Volkmann, J., Schäfer, H., Bötzel, K., Daniels, C., Deutschländer, A., Dillmann, U., Eisner, W., et al. (2006) · New England Journal of Medicine · doi:10.1056/nejmoa060281 · Cited by 2,944
Leucht, S., Cipriani, A., Spineli, L., Mavridis, D., Örey, D., Richter, F., Samara, M., Barbui, C., Engel, R. R., Geddes, J. R., et al. (2013) · The Lancet · doi:10.1016/s0140-6736(13)60733-3 · Cited by 2,561
A Systematic Review of the Prevalence of Schizophrenia
Saha, S., Chant, D., Welham, J., & McGrath, J. (2005) · PLoS Medicine · doi:10.1371/journal.pmed.0020141 · Cited by 2,168
Meltzer, H. Y. (2003) · Archives of General Psychiatry · doi:10.1001/archpsyc.60.1.82 · Cited by 1,393
Laruelle, M., Abi-Dargham, A., van Dyck, C. H., Gil, R., D'Souza, C. D., Erdos, J., McCance, E., Rosenblatt, W., Fingado, C., Zoghbi, S. S., et al. (1996) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.93.17.9235 · Cited by 1,291
PRSice: Polygenic Risk Score software
Euesden, J., Lewis, C. M., & O’Reilly, P. F. (2015) · Bioinformatics · doi:10.1093/bioinformatics/btu848 · Cited by 1,191
Howes, O. D., McCutcheon, R., Agid, O., de Bartolomeis, A., van Beveren, N. J. M., Birnbaum, M. L., Bloomfield, M. A. P., Bressan, R. A., Buchanan, R. W., Carpenter, W. T., et al. (2017) · American Journal of Psychiatry · doi:10.1176/appi.ajp.2016.16050503 · Cited by 1,132
Wykes, T., Steel, C., Everitt, B., & Tarrier, N. (2007) · Schizophrenia Bulletin · doi:10.1093/schbul/sbm114 · Cited by 1,029
Increased baseline occupancy of D 2 receptors by dopamine in schizophrenia
Abi-Dargham, A., Rodenhiser, J., Printz, D., Zea-Ponce, Y., Gil, R., Kegeles, L. S., Weiss, R., Cooper, T. B., Mann, J. J., Van Heertum, R. L., et al. (2000) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.97.14.8104 · Cited by 1,020
McEvoy, J. P., Lieberman, J. A., Stroup, T. S., Davis, S. M., Meltzer, H. Y., Rosenheck, R. A., Swartz, M. S., Perkins, D. O., Keefe, R. S. E., Davis, C. E., et al. (2006) · American Journal of Psychiatry · doi:10.1176/ajp.2006.163.4.600 · Cited by 1,018
Howes, O. D., Kambeitz, J., Kim, E., Stahl, D., Slifstein, M., Abi-Dargham, A., & Kapur, S. (2012) · Archives of General Psychiatry · doi:10.1001/archgenpsychiatry.2012.169 · Cited by 967
A functional neuroanatomy of hallucinations in schizophrenia
Silbersweig, D. A., Stern, E., Frith, C., Cahill, C., Holmes, A., Grootoonk, S., Seaward, J., McKenna, P., Chua, S. E., Schnorr, L., et al. (1995) · Nature · doi:10.1038/378176a0 · Cited by 906
Compliance With Medication Regimens for Mental and Physical Disorders
Cramer, J. A., & Rosenheck, R. (1998) · Psychiatric Services · doi:10.1176/ps.49.2.196 · Cited by 725
Prediction of individual genetic risk to disease from genome-wide association studies
Wray, N. R., Goddard, M. E., & Visscher, P. M. (2007) · Genome Research · doi:10.1101/gr.6665407 · Cited by 725
The environment and susceptibility to schizophrenia
Brown, A. S. (2011) · Progress in Neurobiology · doi:10.1016/j.pneurobio.2010.09.003 · Cited by 664
Chakos, M., Lieberman, J., Hoffman, E., Bradford, D., & Sheitman, B. (2001) · American Journal of Psychiatry · doi:10.1176/appi.ajp.158.4.518 · Cited by 631
Meltzer, H. Y. (1989) · Psychopharmacology · doi:10.1007/bf00442554 · Cited by 602
Siskind, D., McCartney, L., Goldschlager, R., & Kisely, S. (2016) · British Journal of Psychiatry · doi:10.1192/bjp.bp.115.177261 · Cited by 601
Nonadherence with antipsychotic medication in schizophrenia: challenges and management strategies
Haddad, P., Brain, C., & Scott, J. (2014) · Patient Related Outcome Measures · doi:10.2147/prom.s42735 · Cited by 585
Hoffman, R. E., Hawkins, K. A., Gueorguieva, R., Boutros, N. N., Rachid, F., Carroll, K., & Krystal, J. H. (2003) · Archives of General Psychiatry · doi:10.1001/archpsyc.60.1.49 · Cited by 517
Meta-Analysis of the Association of Urbanicity With Schizophrenia
Vassos, E., Pedersen, C. B., Murray, R. M., Collier, D. A., & Lewis, C. M. (2012) · Schizophrenia Bulletin · doi:10.1093/schbul/sbs096 · Cited by 508
The Schizophrenia Patient Outcomes Research Team (PORT): Updated Treatment Recommendations 2009
Kreyenbuhl, J., Buchanan, R. W., Dickerson, F. B., & Dixon, L. B. (2010) · Schizophrenia Bulletin · doi:10.1093/schbul/sbp130 · Cited by 499
Barriers to Employment for People With Schizophrenia
Rosenheck, R., Leslie, D., Keefe, R., McEvoy, J., Swartz, M., Perkins, D., Stroup, S., Hsiao, J. K., Lieberman, J., & CATIE Study Investigators Group (2006) · American Journal of Psychiatry · doi:10.1176/appi.ajp.163.3.411 · Cited by 465
Galderisi, S., Rossi, A., Rocca, P., Bertolino, A., Mucci, A., Bucci, P., Rucci, P., Gibertoni, D., Aguglia, E., Amore, M., et al. (2014) · World Psychiatry · doi:10.1002/wps.20167 · Cited by 463
Lewis, S. W., Barnes, T. R. E., Davies, L., Murray, R. M., Dunn, G., Hayhurst, K. P., Markwick, A., Lloyd, H., & Jones, P. B. (2005) · Schizophrenia Bulletin · doi:10.1093/schbul/sbj067 · Cited by 422
Efficacy of Psychological Therapy in Schizophrenia: Conclusions From Meta-analyses
Pfammatter, M. (2006) · Schizophrenia Bulletin · doi:10.1093/schbul/sbl030 · Cited by 401
Negative Symptoms and Hypofrontality in Chronic Schizophrenia
Wolkin, A. (1992) · Archives of General Psychiatry · doi:10.1001/archpsyc.1992.01820120047007 · Cited by 393
The social and economic burden of treatment-resistant schizophrenia: a systematic literature review
Kennedy, J. L., Altar, C. A., Taylor, D. L., Degtiar, I., & Hornberger, J. C. (2014) · International Clinical Psychopharmacology · doi:10.1097/yic.0b013e32836508e6 · Cited by 392
Cognitive therapy for psychosis in schizophrenia: An effect size analysis
Gould, R. A., Mueser, K. T., Bolton, E., Mays, V., & Goff, D. (2001) · Schizophrenia Research · doi:10.1016/s0920-9964(00)00145-6 · Cited by 389
(1994) · American Journal of Psychiatry · doi:10.1176/ajp.151.12.1744 · Cited by 382
Zimmermann, G., Favrod, J., Trieu, V. H., & Pomini, V. (2005) · Schizophrenia Research · doi:10.1016/j.schres.2005.02.018 · Cited by 371
Electroconvulsive therapy for schizophrenia
Tharyan, P., & Adams, C. E. (2005) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd000076.pub2 · Cited by 354
Management of treatment resistance in schizophrenia
Conley, R. R., & Kelly, D. L. (2001) · Biological Psychiatry · doi:10.1016/s0006-3223(01)01271-9 · Cited by 352
Petrides, G., Malur, C., Braga, R. J., Bailine, S. H., Schooler, N. R., Malhotra, A. K., Kane, J. M., Sanghani, S., Goldberg, T. E., John, M., et al. (2015) · American Journal of Psychiatry · doi:10.1176/appi.ajp.2014.13060787 · Cited by 352
Demjaha, A., Egerton, A., Murray, R. M., Kapur, S., Howes, O. D., Stone, J. M., & McGuire, P. K. (2014) · Biological Psychiatry · doi:10.1016/j.biopsych.2013.06.011 · Cited by 342
Treatment-Resistant Schizophrenia
Elkis, H. (2007) · Psychiatric Clinics of North America · doi:10.1016/j.psc.2007.04.001 · Cited by 338
A Review of Cognitive Training in Schizophrenia
Twamley, E. W., Jeste, D. V., & Bellack, A. S. (2003) · Schizophrenia Bulletin · doi:10.1093/oxfordjournals.schbul.a007011 · Cited by 335
Treatment of the Neuroleptic-Nonresponsive Schizophrenic Patient
Meltzer, H. Y. (1992) · Schizophrenia Bulletin · doi:10.1093/schbul/18.3.515 · Cited by 332
Dopamine Synthesis Capacity in Patients With Treatment-Resistant Schizophrenia
Demjaha, A., Murray, R. M., McGuire, P. K., Kapur, S., & Howes, O. D. (2012) · American Journal of Psychiatry · doi:10.1176/appi.ajp.2012.12010144 · Cited by 325
Lynch, D., Laws, K. R., & McKenna, P. J. (2010) · Psychological Medicine · doi:10.1017/s003329170900590x · Cited by 317
Samara, M. T., Dold, M., Gianatsi, M., Nikolakopoulou, A., Helfer, B., Salanti, G., & Leucht, S. (2016) · JAMA Psychiatry · doi:10.1001/jamapsychiatry.2015.2955 · Cited by 300
Hollis, C. (2000) · American Journal of Psychiatry · doi:10.1176/appi.ajp.157.10.1652 · Cited by 298
PET Activation of Posterior Temporal Regions during Auditory Word Presentation and Verb Generation
Fiez, J. A., Raichle, M. E., Balota, D. A., Tallal, P., & Petersen, S. E. (1996) · Cerebral Cortex · doi:10.1093/cercor/6.1.1 · Cited by 286
Povlsen, U. J., Norrng, U., Fog, R., & Gerlach, J. (1985) · Acta Psychiatrica Scandinavica · doi:10.1111/j.1600-0447.1985.tb01268.x · Cited by 278
Pharmacogenetics of antipsychotic-induced weight gain: review and clinical implications
Lett, T. A. P., Wallace, T. J. M., Chowdhury, N. I., Tiwari, A. K., Kennedy, J. L., & Müller, D. J. (2012) · Molecular Psychiatry · doi:10.1038/mp.2011.109 · Cited by 264
Striatal Presynaptic Dopamine in Schizophrenia, Part II: Meta-Analysis of [18F/11C]-DOPA PET Studies
Fusar-Poli, P., & Meyer-Lindenberg, A. (2013) · Schizophrenia Bulletin · doi:10.1093/schbul/sbr180 · Cited by 262
Freudenreich, O., & Goff, D. C. (2002) · Acta Psychiatrica Scandinavica · doi:10.1034/j.1600-0447.2002.01331.x · Cited by 259
Meta-analysis of studies on genetic variation in 5-HT2A receptors and clozapine response
Arranz, M. J., Munro, J., Sham, P., Kirov, G., Murray, R. M., Collier, D. A., & Kerwin, R. W. (1998) · Schizophrenia Research · doi:10.1016/s0920-9964(98)00032-2 · Cited by 255
Freitas, C., Fregni, F., & Pascual-Leone, A. (2009) · Schizophrenia Research · doi:10.1016/j.schres.2008.11.027 · Cited by 251
Lindström, L. H. (1988) · Acta Psychiatrica Scandinavica · doi:10.1111/j.1600-0447.1988.tb05164.x · Cited by 246
Hamshere, M. L., Walters, J. T. R., Smith, R., Richards, A. L., Green, E., Grozeva, D., Jones, I., Forty, L., Jones, L., Gordon-Smith, K., et al. (2013) · Molecular Psychiatry · doi:10.1038/mp.2012.67 · Cited by 246
At Issue: Defining Treatment Refractoriness in Schizophrenia
Brenner, H. D., Dencker, S. J., Goldstein, M. J., Hubbard, J. W., Keegan, D. L., Kruger, G., Kulhanek, F., Liberman, R. P., Malm, U., & Midha, K. K. (1990) · Schizophrenia Bulletin · doi:10.1093/schbul/16.4.551 · Cited by 242
Gillespie, A. L., Samanaite, R., Mill, J., Egerton, A., & MacCabe, J. H. (2017) · BMC Psychiatry · doi:10.1186/s12888-016-1177-y · Cited by 240
Mouchlianitis, E., Bloomfield, M. A. P., Law, V., Beck, K., Selvaraj, S., Rasquinha, N., Waldman, A., Turkheimer, F. E., Egerton, A., Stone, J., et al. (2016) · Schizophrenia Bulletin · doi:10.1093/schbul/sbv151 · Cited by 225
Twamley, E. W., Doshi, R. R., Nayak, G. V., Palmer, B. W., Golshan, S., Heaton, R. K., Patterson, T. L., & Jeste, D. V. (2002) · American Journal of Psychiatry · doi:10.1176/appi.ajp.159.12.2013 · Cited by 208
Cognitive-behavioral therapy for medication-resistant psychosis: A meta-analytic review
Burns, A. M. N., Erickson, D. H., & Brenner, C. A. (2014) · Psychiatric Services · doi:10.1176/appi.ps.201300213 · Cited by 199
Tiihonen, J., Wahlbeck, K., & Kiviniemi, V. (2009) · Schizophrenia Research · doi:10.1016/j.schres.2009.01.002 · Cited by 194
Age at onset and gender of schizophrenic patients in relation to neuroleptic resistance
(1997) · American Journal of Psychiatry · doi:10.1176/ajp.154.4.475 · Cited by 184
Parametrically Dissociating Speech and Nonspeech Perception in the Brain Using fMRI
Benson, R. R., Whalen, D. H., Richardson, M. L., Swainson, B., Clark, V. P., Lai, S., & Liberman, A. M. (2001) · Brain and Language · doi:10.1006/brln.2001.2484 · Cited by 184
Treatment-Resistant Schizophrenia
Elkis, H., & Buckley, P. F. (2016) · Psychiatric Clinics of North America · doi:10.1016/j.psc.2016.01.006 · Cited by 181
Abi-Dargham, A., & Laruelle, M. (2005) · European Psychiatry · doi:10.1016/j.eurpsy.2004.11.003 · Cited by 179
Iasevoli, F., Giordano, S., Balletta, R., Latte, G., Formato, M. V., Prinzivalli, E., De Berardis, D., Tomasetti, C., & de Bartolomeis, A. (2016) · Progress in Neuro-Psychopharmacology and Biological Psychiatry · doi:10.1016/j.pnpbp.2015.08.010 · Cited by 176
Clozapine as a Model for Antipsychotic Development
Nucifora, F. C., Mihaljevic, M., Lee, B. J., & Sawa, A. (2017) · Neurotherapeutics · doi:10.1007/s13311-017-0552-9 · Cited by 173
Self-citationLally, J., Tully, J., Robertson, D., Stubbs, B., Gaughran, F., & MacCabe, J. H. (2016) · Schizophrenia Research · doi:10.1016/j.schres.2016.01.024 · Cited by 172
Ojemann, G. A. (1978) · Brain and Language · doi:10.1016/0093-934x(78)90030-5 · Cited by 170
Clozapine's effectiveness for patients in state hospitals: results from a randomized trial.
Essock, S. M., Hargreaves, W. A., Covell, N. H., & Goethe, J. (1996) · PubMed · Cited by 169
Valmaggia, L. R., van der Gaag, M., Tarrier, N., Pijnenborg, M., & Slooff, C. J. (2005) · British Journal of Psychiatry · doi:10.1192/bjp.186.4.324 · Cited by 163
Sommer, I. E., Begemann, M. J. H., Temmerman, A., & Leucht, S. (2012) · Schizophrenia Bulletin · doi:10.1093/schbul/sbr004 · Cited by 159
Lindenmayer, J.-P., McGurk, S. R., Mueser, K. T., Khan, A., Wance, D., Hoffman, L., Wolfe, R., & Xie, H. (2008) · Psychiatric Services · doi:10.1176/appi.ps.59.3.241 · Cited by 158
Predictors of treatment resistance in patients with schizophrenia: a population-based cohort study
Wimberley, T., Støvring, H., Sørensen, H. J., Horsdal, H. T., MacCabe, J. H., & Gasse, C. (2016) · The Lancet Psychiatry · doi:10.1016/s2215-0366(15)00575-1 · Cited by 153
Lange, J. J. D.-D., Knegtering, R., & Aleman, A. (2010) · The Journal of Clinical Psychiatry · doi:10.4088/jcp.08r04808yel · Cited by 151
Howes, O. D., Montgomery, A. J., Asselin, M., Murray, R. M., Grasby, P. M., & McGuire, P. K. (2007) · The British Journal of Psychiatry · doi:10.1192/bjp.191.51.s13 · Cited by 146
Kim, E., Howes, O. D., Veronese, M., Beck, K., Seo, S., Park, J. W., Lee, J. S., Lee, Y., & Kwon, J. S. (2016) · Neuropsychopharmacology · doi:10.1038/npp.2016.258 · Cited by 145
Social/Communication Skills, Cognition, and Vocational Functioning in Schizophrenia
Dickinson, D., Bellack, A. S., & Gold, J. M. (2006) · Schizophrenia Bulletin · doi:10.1093/schbul/sbl067 · Cited by 143
Volume of the cingulate and outcome in schizophrenia
Mitelman, S. A., Shihabuddin, L., Brickman, A. M., Hazlett, E. A., & Buchsbaum, M. S. (2004) · Schizophrenia Research · doi:10.1016/j.schres.2004.02.011 · Cited by 142
Jin, Y., Potkin, S. G., Kemp, A. S., Huerta, S., Alva, G., Thai, T. M., Carreon, D., & Bunney, W. E. (2005) · Schizophrenia Bulletin · doi:10.1093/schbul/sbj020 · Cited by 141
Clozapine resistance: Augmentation strategies
Porcelli, S., Balzarro, B., & Serretti, A. (2011) · European Neuropsychopharmacology · doi:10.1016/j.euroneuro.2011.08.005 · Cited by 139
Pinto, A., Pia, S. L., Mennella, R., Giorgio, D., & DeSimone, L. (1999) · Psychiatric Services · doi:10.1176/ps.50.7.901 · Cited by 137
Treatment Refractory Schizophrenia
Lindenmayer, J. (2000) · Psychiatric Quarterly · doi:10.1023/a:1004640408501 · Cited by 135
Slotema, C. W., Aleman, A., Daskalakis, Z. J., & Sommer, I. E. (2012) · Schizophrenia Research · doi:10.1016/j.schres.2012.08.025 · Cited by 133
Young males have a higher risk of developing schizophrenia: a Danish register study
THORUP, A., WALTOFT, B. L., PEDERSEN, C. B., MORTENSEN, P. B., & NORDENTOFT, M. (2007) · Psychological Medicine · doi:10.1017/s0033291707009944 · Cited by 131
Augmentation of clozapine with a second antipsychotic – a meta‐analysis
Taylor, D. M., Smith, L. A., Gee, S., & Nielsen, J. (2011) · Acta Psychiatrica Scandinavica · doi:10.1111/j.1600-0447.2011.01792.x · Cited by 131
Identification of increased genetic risk scores for schizophrenia in treatment-resistant patients
Frank, J., Lang, M., Witt, S. H., Strohmaier, J., Rujescu, D., Cichon, S., Degenhardt, F., Nöthen, M. M., Collier, D. A., Ripke, S., et al. (2014) · Molecular Psychiatry · doi:10.1038/mp.2014.56 · Cited by 126
Polygenic overlap between schizophrenia risk and antipsychotic response: a genomic medicine approach
Ruderfer, D. M., Charney, A. W., Readhead, B., Kidd, B. A., Kähler, A. K., Kenny, P. J., Keiser, M. J., Moran, J. L., Hultman, C. M., Scott, S. A., et al. (2016) · The Lancet Psychiatry · doi:10.1016/s2215-0366(15)00553-2 · Cited by 123
Relapse in schizophrenia: is there a relationship to substance abuse?
Gupta, S., Hendricks, S. E., Kenkel, A. M., Bhatia, S. C., & Haffke, E. A. (1996) · Schizophrenia Research · doi:10.1016/0920-9964(95)00108-5 · Cited by 121
Treatment resistant schizophrenia and response to antipsychotics: A review
Suzuki, T., Remington, G. J., Mulsant, B. H., Rajji, T. K., Uchida, H., Graff‐Guerrero, A., & Mamo, D. C. (2011) · Schizophrenia Research · doi:10.1016/j.schres.2011.09.016 · Cited by 121
Hassan, A., & de Luca, V. (2015) · Schizophrenia Research · doi:10.1016/j.schres.2014.10.048 · Cited by 120
Glutamatergic Neurometabolites in Clozapine-Responsive and -Resistant Schizophrenia
McIlwain, M., Anderson, V. M., Pillai, A., Kydd, R. R., & Russell, B. R. (2015) · The International Journal of Neuropsychopharmacology · doi:10.1093/ijnp/pyu117 · Cited by 118
Kindler, J., Homan, P., Jann, K., Federspiel, A., Flury, R., Hauf, M., Strik, W., Dierks, T., & Hubl, D. (2013) · Biological Psychiatry · doi:10.1016/j.biopsych.2012.06.019 · Cited by 112
Rocca, P., Montemagni, C., Zappia, S., Piterà, R., Sigaudo, M., & Bogetto, F. (2014) · Psychiatry Research · doi:10.1016/j.psychres.2014.04.018 · Cited by 111
Extensive Gray Matter Volume Reduction in Treatment-Resistant Schizophrenia
Anderson, V. M., Goldstein, M. E., Kydd, R. R., & Russell, B. (2015) · The International Journal of Neuropsychopharmacology · doi:10.1093/ijnp/pyv016 · Cited by 108
Zoccali, R. A., Muscatello, M. R. A., Bruno, A., Cambria, R., Micò, U., Spina, E., & Meduri, M. (2007) · Schizophrenia Research · doi:10.1016/j.schres.2007.02.009 · Cited by 106
Combined Electroconvulsive-Clozapine Therapy
Kupchik, M., Spivak, B., Mester, R., Reznik, I., Gonen, N., Weizman, A., & Kotler, M. (2000) · Clinical Neuropharmacology · doi:10.1097/00002826-200001000-00003 · Cited by 104
Neuroimaging findings in treatment-resistant schizophrenia: A systematic review
Nakajima, S., Takeuchi, H., Plitman, E., Fervaha, G., Gerretsen, P., Caravaggio, F., Chung, J. K., Iwata, Y., Remington, G. J., & Graff‐Guerrero, A. (2015) · Schizophrenia Research · doi:10.1016/j.schres.2015.01.043 · Cited by 103
Pathophysiologic mechanisms in the pathogenesis and clinical course of schizophrenia.
Lieberman, J. A. (1999) · PubMed · Cited by 102
Profiling cognitive impairment in treatment-resistant schizophrenia patients
Frydecka, D., Beszłej, J. A., Gościmski, P., Kiejna, A., & Misiak, B. (2015) · Psychiatry Research · doi:10.1016/j.psychres.2015.11.028 · Cited by 100
Transcranial magnetic stimulation (TMS) for schizophrenia
Dougall, N. J., Maayan, N., Soares‐Weiser, K., McDermott, L. M., & McIntosh, A. M. (2015) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd006081.pub2 · Cited by 99
The Role of Clozapine in Treatment-Resistant Schizophrenia
Kane, J. M., & Correll, C. U. (2016) · JAMA Psychiatry · doi:10.1001/jamapsychiatry.2015.2966 · Cited by 98
Sarin, F., Wallin, L., & Widerlöv, B. (2011) · Nordic Journal of Psychiatry · doi:10.3109/08039488.2011.577188 · Cited by 97
Factor structure of the MATRICS Consensus Cognitive Battery (MCCB) in schizophrenia
Burton, C. Z., Vella, L., Harvey, P. D., Patterson, T. L., Heaton, R. K., & Twamley, E. W. (2013) · Schizophrenia Research · doi:10.1016/j.schres.2013.02.026 · Cited by 96
COHEN, E., Bernardo, M., Masana, J., Arrufat, F. J., NAVARRO, V., Valls‐Solé, J., Boget, T., Barrantes‐Vidal, N., Catarineu, S., FONT, M., et al. (1999) · Journal of Neurology Neurosurgery & Psychiatry · doi:10.1136/jnnp.67.1.129 · Cited by 93
Relation of Familial Schizophrenia to Negative Symptoms But Not to the Deficit Syndrome
Malaspina, D., Goetz, R. R., Yale, S., Berman, A., Friedman, J. H., Trémeau, F., PRINTZ, D. J., AMADOR, X. F., Johnson, J., Brown, A. S., et al. (2000) · American Journal of Psychiatry · doi:10.1176/appi.ajp.157.6.994 · Cited by 93
Mowry, B. J., & Gratten, J. (2012) · Molecular Psychiatry · doi:10.1038/mp.2012.34 · Cited by 91
de Bartolomeis, A., Balletta, R., Giordano, S., Buonaguro, E. F., Latte, G., & Iasevoli, F. (2013) · Psychiatry Research · doi:10.1016/j.psychres.2013.06.042 · Cited by 87
Kubera, K. M., Sambataro, F., Vasić, N., Wolf, N. D., Frasch, K., Hirjak, D., Thomann, P. A., & Wolf, R. C. (2013) · Progress in Neuro-Psychopharmacology and Biological Psychiatry · doi:10.1016/j.pnpbp.2013.11.015 · Cited by 86
Rachid, F. (2017) · Psychiatry Research · doi:10.1016/j.psychres.2017.09.009 · Cited by 86
McGrath, J. J., Mortensen, P. B., Visscher, P. M., & Wray, N. R. (2013) · Schizophrenia Bulletin · doi:10.1093/schbul/sbt108 · Cited by 82
Predictors of Outcome in Schizophrenia
Murray, R. M., & van Os, J. (1998) · Journal of Clinical Psychopharmacology · doi:10.1097/00004714-199804001-00002 · Cited by 80
Coppens, H. J., Slooff, C. J., Paans, A. M. J., Wiegman, T., Vaalburg, W., & Korf, J. (1991) · Biological Psychiatry · doi:10.1016/0006-3223(91)90132-6 · Cited by 80
Zheng, W., Cao, X., Ungvari, G. S., Xiang, Y., Guo, T., Liu, Z., Wang, Y., Forester, B. P., Seiner, S. J., & Xiang, Y. (2016) · PLoS ONE · doi:10.1371/journal.pone.0156510 · Cited by 78
The Origins of Electroconvulsive Therapy (ECT).
Endler, N. S. (1988) · PubMed · Cited by 77
Klein, J., Hadar, R., Götz, T., Männer, A., Eberhardt, C., Baldassarri, J., Schmidt, T. T., Kupsch, A. R., Heinz, A., Morgenstern, R., et al. (2012) · Brain stimulation · doi:10.1016/j.brs.2012.09.004 · Cited by 76
Joober, R., Rouleau, G. A., Lal, S., Dixon, M. J., O’Driscoll, G. A., Palmour, R. M., Annable, L., Bloom, D., Lalonde, P., Labelle, A., et al. (2002) · Schizophrenia Research · doi:10.1016/s0920-9964(01)00279-1 · Cited by 75
Association Study of 27 Annotated Genes for Clozapine Pharmacogenetics
Lee, S., Ryu, S., Kim, S.-R., Kim, M.-J., Kim, S., Kim, J., Lee, S., & Hong, K. S. (2012) · Journal of Clinical Psychopharmacology · doi:10.1097/jcp.0b013e31825ac35c · Cited by 73
Bartlett, E. J., Brodie, J. D., Simkowitz, P., Schl"sser, R., Dewey, S. L., Lindenmayer, J., Rusinek, H., Wolkin, A., Cancro, R., & Schiffer, W. K. (1998) · American Journal of Psychiatry · doi:10.1176/ajp.155.3.337 · Cited by 70
Perez, S. M., Shah, A., Asher, A. M., & Lodge, D. J. (2012) · The International Journal of Neuropsychopharmacology · doi:10.1017/s1461145712001344 · Cited by 67
New therapeutic approaches for treatment-resistant schizophrenia: A look to the future
Miyamoto, S., Jarskog, L. F., & Fleischhacker, W. W. (2014) · Journal of Psychiatric Research · doi:10.1016/j.jpsychires.2014.07.001 · Cited by 65
Bikovski, L., Hadar, R., Soto‐Montenegro, M. L., Klein, J., Weiner, I., Desco, M., Pascau, J., Winter, C., & Hamani, C. (2016) · Experimental Neurology · doi:10.1016/j.expneurol.2016.06.012 · Cited by 64
A Polygenic Risk Score Associated with Measures of Depressive Symptoms Among Older Adults
Levine, M. E., Crimmins, E. M., Prescott, C. A., Phillips, D. F., Arpawong, T. E., & Lee, J. (2014) · Biodemography and Social Biology · doi:10.1080/19485565.2014.952705 · Cited by 63
Cognitive Behavioral Therapy for Schizophrenia
Rector, N. A., & Beck, A. T. (2012) · The Journal of Nervous and Mental Disease · doi:10.1097/nmd.0b013e31826dd9af · Cited by 63
A Preliminary Controlled Trial of Cognitive Behavioral Therapy in Clozapine-Resistant Schizophrenia
Barretto, E. M. D. P., Kayo, M., Avrichir, B. S., de Sá, A. R., Camargo, M. D. G. M., Napolitano, I. C., Nery, F. G., Pinto, J. A., Bannwart, S., Scemes, S., et al. (2009) · The Journal of Nervous and Mental Disease · doi:10.1097/nmd.0b013e3181be7422 · Cited by 62
Reichert, A., Kreiker, S., Mehler‐Wex, C., et al. (2008) · Child and Adolescent Psychiatry and Mental Health · doi:10.1186/1753-2000-2-6 · Cited by 61
Pharmacogenetics of antipsychotics: recent progress and methodological issues
Zhang, J., & Malhotra, A. K. (2012) · Expert Opinion on Drug Metabolism & Toxicology · doi:10.1517/17425255.2013.736964 · Cited by 61
Treatment Response in First-episode Schizophrenia
Schennach, R., Riedel, M. J., Musil, R., & Möller, H. (2012) · Clinical Psychopharmacology and Neuroscience · doi:10.9758/cpn.2012.10.2.78 · Cited by 57
Plewnia, C., Schober, F., Rilk, A. J., Buchkremer, G., Reimold, M., Wächter, T., Breit, S., Weiß, D., Krüger, R., & Freudenstein, D. (2008) · The International Journal of Neuropsychopharmacology · doi:10.1017/s1461145708009188 · Cited by 55
Mouse models of gene–environment interactions in schizophrenia
Kannan, G., Sawa, A., & Pletnikov, M. V. (2013) · Neurobiology of Disease · doi:10.1016/j.nbd.2013.05.012 · Cited by 54
Self-citationQuarantelli, M., Palladino, O., Prinster, A., Schiavone, V., Carotenuto, B., Brunetti, A., Marsili, A., Casiello, M., Muscettola, G., Salvatore, M., et al. (2014) · BioMed Research International · doi:10.1155/2014/325052 · Cited by 51
Cognitive function in schizophrenia: conflicting findings and future directions
Moustafa, A. A., Garami, J. K., Mahlberg, J., Golembieski, J., Kéri, S., Misiak, B., & Frydecka, D. (2016) · Reviews in the Neurosciences · doi:10.1515/revneuro-2015-0060 · Cited by 50
Pharmacogenetics of clozapine treatment response and side-effects in schizophrenia: an update
Sriretnakumar, V., Huang, E., & Müller, D. J. (2015) · Expert Opinion on Drug Metabolism & Toxicology · doi:10.1517/17425255.2015.1075003 · Cited by 48
Crespo‐Facorro, B., de la Foz, V. O., Ayesa‐Arriola, R., Pérez‐Iglesias, R., Mata, I. F., Suárez‐Pinilla, P., Tabarés‐Seisdedos, R., & Vázquez‐Barquero, J. L. (2013) · Progress in Neuro-Psychopharmacology and Biological Psychiatry · doi:10.1016/j.pnpbp.2013.02.009 · Cited by 48
Otani, V. H. O., Shiozawa, P., Cordeiro, Q., & Uchida, R. R. (2014) · International Journal of Psychiatry in Clinical Practice · doi:10.3109/13651501.2014.980830 · Cited by 48
Ma, J., & Leung, L.-W. S. (2014) · Behavioural Brain Research · doi:10.1016/j.bbr.2014.03.010 · Cited by 45
Xu, Q., Wu, X. L., Li, M., Huang, H., Minică, C. C., Yi, Z., Wang, G., Shen, L., Xing, Q., Shi, Y., et al. (2015) · The Pharmacogenomics Journal · doi:10.1038/tpj.2015.61 · Cited by 44
Increased rare duplication burden genomewide in patients with treatment-resistant schizophrenia
Martin, A. K., & Mowry, B. J. (2015) · Psychological Medicine · doi:10.1017/s0033291715001701 · Cited by 44
Molina, V., Reig, S., Sanz, J., Palomo, T., Benito, C., Sarramea, F., Pascau, J., Sánchez, J. C., Martín‐Loeches, M., Muñoz, F., et al. (2007) · Progress in Neuro-Psychopharmacology and Biological Psychiatry · doi:10.1016/j.pnpbp.2007.08.017 · Cited by 43
Treatment-refractory schizophrenia
Caspi, A., Davidson, M., & Tamminga, C. A. (2004) · Dialogues in Clinical Neuroscience · doi:10.31887/dcns.2004.6.1/acaspi · Cited by 41
Treatment-resistant schizophrenia: Evidence-based strategies
Zink, M., & Englisch, S. (2012) · Mens Sana monographs · doi:10.4103/0973-1229.91588 · Cited by 40
Lawrie, S. M., Ingle, G. T., Santosh, C., Rogers, A. C., Rimmington, J. E., Naidu, K. P., Best, J. J. K., O’Carroll, R. E., Goodwin, G. M., Ebmeier, K. P., et al. (1995) · The British Journal of Psychiatry · doi:10.1192/bjp.167.2.202 · Cited by 39
Corripio, I., Sarró, S., McKenna, P. J., Molet, J., Álvarez, E., Pomarol‐Clotet, E., & Portella, M. J. (2016) · Biological Psychiatry · doi:10.1016/j.biopsych.2016.03.1049 · Cited by 36
Efficacy of Electroconvulsive Therapy in Treatment Resistant Schizophreinia : A double-blind study.
Goswami, U., Kumar, U., & Singh, B. (2003) · PubMed · Cited by 35
Huang, E., Maciukiewicz, M., Zai, C. C. H., Tiwari, A. K., Li, J., Potkin, S. G., Lieberman, J. A., Meltzer, H. Y., Müller, D. J., & Kennedy, J. L. (2015) · Pharmacogenomics · doi:10.2217/pgs.15.155 · Cited by 35
Akamine, Y., Sugawara-Kikuchi, Y., Uno, T., Shimizu, T., & Miura, M. (2016) · Annals of Clinical Biochemistry International Journal of Laboratory Medicine · doi:10.1177/0004563216686377 · Cited by 34
Joober, R., Rouleau, G. A., Lal, S., Bloom, D., Lalonde, P., Labelle, A., & Benkelfat, C. (2005) · Schizophrenia Research · doi:10.1016/j.schres.2005.01.008 · Cited by 32
The role of ethnicity in treatment refractory schizophrenia
Teo, C., Borlido, C., Kennedy, J. L., & Luca, V. D. (2012) · Comprehensive Psychiatry · doi:10.1016/j.comppsych.2012.07.002 · Cited by 29
Remington, G. J., Kapur, S., Foussias, G., Agid, O., Mann, S. W., Borlido, C., Richards, S., & Javaid, N. (2011) · Journal of Clinical Psychopharmacology · doi:10.1097/jcp.0b013e31823f913e · Cited by 28
Yeo, R. A., Gangestad, S. W., Liu, J., Ehrlich, S., Thoma, R. J., Pommy, J. M., Mayer, A. R., Schulz, S. C., Wassink, T. H., Morrow, E. M., et al. (2012) · Biological Psychiatry · doi:10.1016/j.biopsych.2012.10.013 · Cited by 24
Therapy-Resistant Schizophrenia
(2010) · Advances in biological psychiatry · doi:10.1159/isbn.978-3-8055-9512-4 · Cited by 21
Analysis of differential gene expression mediated by clozapine in human postmortem brains
Lee, B. J., Marchionni, L., Andrews, C. E., Norris, A. L., Nucifora, L. G., Wu, Y. C., Wright, R. A., Pevsner, J., Ross, C. A., Margolis, R. L., et al. (2016) · Schizophrenia Research · doi:10.1016/j.schres.2016.12.017 · Cited by 19
Self-citationKayo, M., Tassell, I., Hiroce, V., Menezes, A. K. P. M., & Elkis, H. (2012) · Clinics · doi:10.6061/clinics/2012(12)20 · Cited by 12
Andrews, C. E., Baker, K. K., Howell, C., Cuerdo, A., Roberts, J. A., Chaudhary, A., Lechich, S., Nucifora, L. G., Vaidya, D. M., Mojtabai, R., et al. (2017) · Psychiatric Services · doi:10.1176/appi.ps.201600334 · Cited by 11
Self-citationGenetic Overlap Between Antipsychotic Response and Susceptibility to Schizophrenia
Ikeda, M., Yoshimura, R., Hashimoto, R., Kondo, K., Saito, T., Shimasaki, A., Ohi, K., Tochigi, M., Kawamura, Y., Nishida, N., et al. (2014) · Journal of Clinical Psychopharmacology · doi:10.1097/jcp.0000000000000268 · Cited by 10
Martin, A. K., Robinson, G. A., Reutens, D. C., & Mowry, B. J. (2015) · American Journal of Medical Genetics Part B Neuropsychiatric Genetics · doi:10.1002/ajmg.b.32321 · Cited by 7
Therapeutic Brain Stimulation in Treatment-Resistant Schizophrenia
Rosenquist, P. B., Ahmed, A. O., & McCall, W. V. (2014) · Springer eBooks · doi:10.1007/978-3-642-45257-4_8 · Cited by 6
Neuropsychology of Treatment-Resistant Schizophrenia
Woodward, N. D., & Meltzer, H. Y. (2010) · Advances in biological psychiatry · doi:10.1159/000319807 · Cited by 6
Cited by
Altered gut microbiota and mucosal immunity in patients with schizophrenia
Xu, R., Wu, B., Liang, J., He, F., Gu, W., Li, K., Luo, Y., Chen, J., Gao, Y., Wu, Z., et al. (2020) · Brain Behavior and Immunity · doi:10.1016/j.bbi.2019.06.039 · Cited by 198
Fernández‐Aranda, F., Treasure, J., Paslakis, G., Agüera, Z., Giménez, M., Granero, R., Sánchez, I., Serrano‐Troncoso, E., Gorwood, P., Herpertz‐Dahlmann, B., et al. (2021) · European Eating Disorders Review · doi:10.1002/erv.2822 · Cited by 99
Neural Circuitry of Salience and Reward Processing in Psychosis
Kesby, J. P., Murray, G. K., & Knolle, F. (2023) · Biological Psychiatry Global Open Science · doi:10.1016/j.bpsgos.2021.12.003 · Cited by 55
Galido, P. V., Butala, S., Chakerian, M., & Agustines, D. (2023) · Cureus · doi:10.7759/cureus.38166 · Cited by 29
Metadata
- Authors
- Nucifora, F. C., Woznica, E., Lee, B. J., Cascella, N., & Sawa, A.
- Venue
- Neurobiology of Disease
- Publisher
- Elsevier BV
- Published
- 2019-11
- Volume
- 131
- Pages
- 104257
- ISSN
- 0969-9961 (ISSN-L)
- OpenAlex
- W2889058327
- Cited by
- 304
- References
- 157
- FWCI
- 8.50
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.